Le Lézard
Classified in: Health, Science and technology
Subjects: Photo/Multimedia, Personnel

IPS Appoints Jim Stephanou as New CEO


IPS, a leading provider of architecture, engineering, procurement, construction management, and validation services for the life sciences sector, announces the appointment of Jim Stephanou, as its new Chief Executive Officer (CEO) to lead the company into its next phase of growth.

Mr. Stephanou is a well-recognized and accomplished leader in the Pharmaceutical Industry with over thirty years of experience in manufacturing operations and engineering. His most recent role was Vice President, Global Engineering Solutions at Merck & Co., Inc., a position he held for eight years. During that time, he was responsible for managing and overseeing one of the largest capital investment cycles of any pharmaceutical operating company. Before joining Merck, Mr. Stephanou held several leadership positions at Bayer Corporation and Lyondell Basell Industries for over two decades. He holds a mechanical engineering degree from Drexel University.

Mr. Stephanou will report to Dave Goswami, the Global CEO of IPS Enterprise. When discussing the new CEO appointment for IPS Life Science, Mr. Goswami stated, "We are excited to have someone of Jim's caliber to take on the CEO role. Jim is just the right person to lead IPS Life Science as we continue on our unwavering commitment to providing EPCMV services to the life sciences industry. I've had the pleasure of working with and getting to know Jim through the many years supporting Merck as one of our largest clients. He has demonstrated remarkable leadership capabilities and possesses the skills necessary to lead IPS into the future. I have full faith in his ability to build upon our past accomplishments and drive the company to even greater heights. This appointment is a part of our organizational strategy to achieve our ambitious growth goals. It will allow me to focus on our enterprise level targets and to fulfill IPS' overall mission."

Jim Stephanou shared his excitement about joining IPS, saying, "I am thrilled and honored to have the opportunity to lead such a respected and successful organization. IPS has been in the midst of phenomenal growth that has led to becoming a part of the Berkshire Hathaway's group of companies. It is truly an exciting time to join the company. IPS has a strong foundation, a talented team, and a reputation for excellence in the life sciences industry. I look forward to working closely with the team to further enhance our global brand and market presence and deliver innovative solutions to meet our clients' needs."

About IPS

IPS-Integrated Project Services LLC, a Berkshire Hathaway Company, is a global leader in developing innovative business solutions for capital investments in the life science and data center sectors. Through operational expertise and industry-leading knowledge, skill, and passion, IPS provides architecture, engineering, project controls, construction management, and compliance services in the life science industry that allow clients to develop and manufacture life-impacting products. Its newest acquisition, Linesight specializes in cost, schedule, risk, program, and project management services in various market sectors, including data centers, life sciences, and high-tech industries. IPS Enterprise has over 3,200 professionals in over 45 offices across 17 countries in the Americas, Europe, Asia Pacific, Southeast Asia, Australia, and the Middle East. For further information, please visit www.ipsdb.com.


These press releases may also interest you

at 17:07
The American Concrete Institute along with the ACI Saudi Chapter will co-host the ACI Concrete Conference of Codes, Standards, and Best Practices in Riyadh, Saudi Arabia on November 28-29, 2023. The 2-day conference will be held at the Hilton Riyadh...

at 17:05
Quanterix Corporation , a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will speak on a panel at Goldman Sachs Alzheimer's Disease Day on Tuesday, October...

at 17:05
MEI Pharma, Inc. (the "MEI" or "the Company") today issued the following statement in response to the consent solicitation initiated by a group led by Anson Advisors Inc. and Cable Car Capital LLC. The MEI Board of Directors and management team...

at 17:05
BlackBerry Limited today reported financial results for the three months ended August 31, 2023 (all figures in U.S. dollars and U.S. GAAP, except...

at 17:01
DelveInsight's Neuroblastoma Market Insights report includes a comprehensive understanding of current treatment practices, neuroblastoma emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to...

at 17:00
Medicenna Therapeutics Corp. ("Medicenna" or the "Company") , a clinical-stage immuno-oncology company focused on the development of novel Superkines, today announced the voting results from the Company's annual and special meeting of shareholders...



News published on and distributed by: